Form 4: Genelux CFO Lourie S. Zak Reports Acquisition and Disposal of Common Stock and Warrants
SEC Form 4
Genelux Corp's CFO, Lourie S. Zak, reports acquiring and disposing of 31,250 shares of common stock and warrants.
Summary
- On May 29, 2024, Lourie S. Zak, the Chief Financial Officer of Genelux Corporation, reported a transaction involving the acquisition and disposal of 31,250 shares of common stock.
- These shares were sold together with warrants to purchase common stock, with a combined price of $4.00 per share and warrant.
- Zak also reported acquiring 31,250 common stock warrants with an exercise price of $5.25, exercisable from May 29, 2024, and expiring on May 29, 2029.
Sentiment
Score: 5
Explanation: This is a neutral filing, simply reporting transactions. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the biotechnology industry. Investors monitor these filings for insights into management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders may be interested in the CFO's transactions as an indicator of management's view of the company's value.
Key Dates
| Date | Description |
|---|---|
| 05/29/2024 | Date of earliest transaction: acquisition and disposal of common stock and warrants. |
| 05/29/2024 | Date the acquired warrants become exercisable. |
| 05/29/2029 | Expiration date of the acquired warrants. |
| 06/07/2024 | Date of signature by Attorney-in-Fact, Thomas Zindrick. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.